Dear Maryland Breast and Cervical Cancer Provider:

Thank you for providing breast cancer screening for uninsured or underinsured women aged 40-64 enrolled in the Maryland Breast and Cervical Cancer Program (BCCP). The Maryland BCCP is a grantee of the National Breast and Cervical Cancer Early Detection Program, funded by the Centers for Disease Control and Prevention. The policies of the national program are based on evidence in scientific literature and recommendations from national organizations such as the American Cancer Society, the United States Preventive Services Task Force, the National Comprehensive Cancer Network and the American College of Radiology.

We are pleased to enclose the revised “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis” developed by the Medical Advisory Committee for the BCCP to serve as guidelines for the management of women receiving breast cancer screening and diagnostic services through the BCCP.

The changes include:

- Indications for when a MRI is allowable; and
- Updated wording for breast density to reflect the 2013 ACR® BI-RADS Atlas reporting system 5th edition.

We appreciate your cooperation in using the new guidelines. If you have any questions regarding the new “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis” for the Maryland Breast and Cervical Program, please contact Ken Lin Tai, M.D., M.P.H., Medical Director for the Center for Cancer Prevention and Control (CCPC) at 410-767-2036 or kenlin.tai@maryland.gov.

Sincerely,

Stanley Watkins, M.D.
Chairman, Medical Advisory Committee
Maryland Breast and Cervical Cancer Program

Enclosure

Cc    Courtney Lewis, MPH    Dawn Henninger, RN, MS    Local Program Coordinators
      Ken Lin Tai, MD, MPH    Holly Harshbarger, RN, BS
Minimal Clinical Elements for Breast Cancer Detection and Diagnosis
Maryland Breast and Cervical Cancer Program
Maryland DHMH, Center for Cancer Prevention and Control
June 2015

Goal:
The goal of the Minimal Clinical Elements for Breast Cancer Detection and Diagnosis is to provide clients of the Maryland Breast and Cervical Cancer Program (BCCP) with optimal, up-to-date screening for breast cancer and management of findings.

Objective:
- To provide clinical guidelines for breast cancer screening and diagnostic testing including interpretation and management of results of clinical breast examination, mammography, and diagnostic testing.
- To outline appropriate management and approved indications for procedure payment.

Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program—Breast Cancer Minimal Clinical Elements

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Maryland Breast and Cervical Cancer Program (BCCP)—</td>
<td></td>
</tr>
<tr>
<td>Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Diagnostic Testing when referred by a clinician for follow-up for an abnormal breast screening exam.</td>
<td></td>
</tr>
<tr>
<td>A. BCCP Eligibility and Procedures for Screening or Initial Testing</td>
<td>3</td>
</tr>
<tr>
<td>B. Eligibility for Diagnostic Testing in the BCCP</td>
<td>4</td>
</tr>
<tr>
<td>II. Findings, Management of Results, Additional Procedures, and Program Coverage</td>
<td></td>
</tr>
<tr>
<td>A. Results and Reports</td>
<td>5</td>
</tr>
<tr>
<td>B. Management of Findings of CBE, Initial Mammogram, and Testing</td>
<td>6</td>
</tr>
<tr>
<td>C. Additional Procedures and Program Coverage</td>
<td>6</td>
</tr>
</tbody>
</table>

Attachment A
Flow Charts of the Maryland Breast and Cervical Cancer Program: Management of Clinical Breast Examination and Mammogram Results

| I. Management when the Clinical Breast Exam is Normal/Benign | 10 |
| II. Management when the Clinical Breast Exam is Abnormal | 11 |
Members of the Breast Cancer Subcommittee of the BCCP Medical Advisory Committee:

Stanley Watkins, M.D., Chairman
   Hematologist/Oncologist
   Annapolis Medical Specialists
   Assistant Professor of Oncology, The Johns Hopkins School of Medicine (part time)

Cecilia Brennecke, M.D.
   Medical Director, Johns Hopkins Imaging
   Diagnostic Radiology

Robert Brookland, M.D.
   Chairman, Department of Radiation Oncology
   Greater Baltimore Medical Center

Regina Hampton, M.D. FACS
   Medical Director, Center for Women’s Wellness
   Doctor’s Community Hospital

Kathy J. Helzlsouer, M.D., M.H.S.
   Director, The Prevention and Research Center
   The Weinberg Center for Women’s Health and Medicine
   Mercy Medical Center

Nagi Khouri, M.D.
   Associate Professor of Radiology and Radiological Science
   Associate Professor of Oncology
   Johns Hopkins Medical Institutions

Lorraine Tafra, M.D.
   Breast Surgery
   Anne Arundel Medical Center

Staff for the Breast Cancer Subcommittee
Center for Cancer Prevention and Control, Maryland Dept. of Health and Mental Hygiene
   Courtney Lewis, M.P.H., Director, CCPC
   Ken Lin Tai, M.D., M.P.H., Medical Director, CCPC
   Dawn Henninger, R.N., M.S., Program Manager, BCCP
   Holly Harshbarger, R.N., B.S. Program Nurse Consultant, BCCP
Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program

Breast Cancer Minimal Clinical Elements (MCE)

I. Maryland Breast and Cervical Cancer Program (BCCP)—Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Diagnostic Testing When Referred by a Clinician for Follow-up for an Abnormal Breast Screening Exam

A. BCCP Eligibility and Procedures for Screening or Initial Testing
1. A woman is eligible for breast cancer screening with clinical breast examination (CBE) and mammogram in the BCCP regardless of symptoms, risk factors, or prior breast cancer/findings if she:
   a. Is 40 – 64 years old or 65+ without Medicare Part B;
   b. Meets income eligibility of household income ≤250% of the Federal Poverty Guideline;
   c. Has no health insurance, has health insurance that does not cover breast cancer screening, or has coverage but has not met deductible for the year, and/or a patient contribution amount for applicable procedures to include copays and co-insurance; and
   d. Has not had bilateral mastectomies.
2. A woman should have a diagnostic mammogram if a woman has:
   a. A CBE with results that include:
      i. Nipple discharge that is:
         (a) Bloody;
         (b) Crystal clear (like water); or
         (c) Any other color or clarity (for example, yellow, white, milky, gray, green) if the discharge is unilateral, single duct, and spontaneous.
      ii. Discrete palpable mass—suspicious for cancer;
      iii. Nipple/areolar scaliness; or
      iv. Skin dimpling/retraction;
   b. A recommendation for a diagnostic mammogram from the Medical Case Manager.
3. A woman should have a screening mammogram as the annual exam if the woman has:
   a. A CBE with Normal findings or a CBE with Benign findings, including:
      i. Nipple discharge that does not meet the requirement for diagnostic mammogram (2., a., i., above);
      ii. Breast implant(s);
      iii. Fibrocystic changes,
      iv. Mastitis;
      v. “Lumpy” breasts;
vi. Family history of breast cancer (premenopausal breast cancer in sister/mother); or
vii. Prior benign biopsy (within past year) when surgeon or radiologist recommends screening mammogram.

b. A history of negative screening mammogram(s) (American College of Radiology, Breast Imaging and Database Reporting System [BI-RADS] category 1, negative, or BI-RADS 2, benign finding).

4. A woman with a prior history of breast cancer (in situ or invasive, in patient who has not had bilateral mastectomies) should have a:
   a. Diagnostic mammogram for 5 years post diagnosis then;
   b. May resume screening mammogram after 5 years at the discretion of the medical case manager, radiologist and client.

5. CBE should be performed 90 days prior to the screening mammogram.
   a. Each breast should be examined including the retroareolar and peripheral areas and the upper lateral quadrant into the axilla.
   b. The preferred method of CBE is the strip technique using three levels of pressure in small circular motions with pad of three middle fingers without lubrication (MammaCare® method).

B. Eligibility for Diagnostic Testing in the BCCP

A woman is eligible for breast cancer diagnostic testing in the BCCP if she:

1. Is 40 – 64 years old, or 65+ without Medicare Part B;

2. Meets income eligibility of ≤250% of the Federal Poverty Guideline;

3. Has no health insurance, has health insurance that does not cover breast cancer diagnostic testing/visits, or has coverage but has not met deductible for the year, and/or a patient contribution amount for applicable procedures to include copays and co-insurance.

4. Has not had bilateral mastectomies; and

5. Provides the BCCP with a recommendation from a clinician for diagnostic workup and test results of:
   a. CBE requiring further diagnosis (see I. A. 2. a.);
   b. Mammogram requiring further diagnosis;
   c. Ultrasound abnormal finding other than simple cyst(s); or
   d. Persistent, unexplained, localized pain in the breast with a negative mammogram.
II. Findings, Management of Results, Additional Procedures, and Program Coverage

A. Results and Reports

1. CBE findings:
   a. Should be reported as:
      i. Normal exam
      ii. Benign findings
      iii. Abnormal findings:
         1. Nipple discharge that is bloody, crystal clear (like water) or any other color or clarity (for example, yellow, white, milky, gray, green) if the discharge is unilateral, single duct, and spontaneous.
         2. Discrete palpable mass—suspicious for cancer
         3. Nipple/areolar scaliness
         4. Skin dimpling/retraction
   b. CBE should report whether there are breast implants; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.
   c. CBE should report whether the patient has had a lumpectomy or a mastectomy and which breast was affected; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.

2. Mammogram findings should be reported using American College of Radiology BI-RADS® (Breast Imaging-Reporting and Database System) Assessment Categories:

   a. Assessment is Incomplete
      0 Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison

   b. Assessment is Complete – Final Categories
      1 Negative
      2 Benign Finding(s)
      3 Probably Benign Finding – Initial Short-Interval Follow-Up Suggested
      4 Suspicious Abnormality – Biopsy Should Be Considered
      5 Highly Suggestive of Malignancy – Appropriate Action Should Be Taken
      6 Known Biopsy-Proven Malignancy – Appropriate Action Should Be Taken
         (Category reserved for lesions identified on imaging study with biopsy proof of malignancy prior to definitive therapy)

      Ref. The American College of Radiology BI-RADS® ATLAS and MQSA: Frequently Asked Questions (Updated: 7/1/09)

   c. Breast composition on mammogram should be described for all patients using the following patterns:
      i. The breasts are almost entirely fatty
      ii. There are scattered areas of fibroglandular density
      iii. The breasts are heterogeneously dense, which may obscure small masses
      iv. The breasts are extremely dense, which lowers the sensitivity of mammography

3. **Ultrasound definitions:** The terms “simple cyst,” “complicated cyst,” and “complex cyst” are defined by the radiologist and stated in the report of an ultrasound examination.

4. The radiologist’s diagnostic workup/evaluation report should include the results of the diagnostic mammogram, ultrasound (when performed), CBE, and the correlation of each test with each other.

**B. Management of Findings of CBE, Initial Mammogram, and Testing**

1. **See Attachment A.** Flow Charts of the Maryland Breast and Cervical Cancer Program: Management of Clinical Breast Examination and Mammogram Results.

2. A woman with persistent, unexplained, localized pain in the breast should be evaluated by a breast specialist or surgeon.

3. If a radiologist recommends obtaining results or copies of prior mammograms following a BI-RADS category 0 result, local programs should assist in obtaining the results or copies.

4. Image-guided percutaneous needle biopsy is the diagnostic procedure of choice for image-detected abnormalities, with few exceptions.

5. When a non-palpable or questionably palpable mass that was found on imaging is excised, the specimen should be verified by using the appropriate imaging modality while the patient is still in the operating room.

6. At least one breast tissue specimen positive for cancer should be tested for tumor markers (e.g. estrogen/progesterone receptors, her2neu etc.) to guide clinical management.

**C. Additional Procedures and Program Coverage**

1. Providers should consult with the local BCCP for questions about coverage for payment of procedures.

2. Magnetic Resonance Imaging (MRI)
   a. The Maryland BCCP will reimburse for screening breast MRI performed in conjunction with a mammogram when a client has the following indications:
      i. Lifetime risk of breast cancer of about 20% to 25% or greater, according to risk assessment tools that are based mainly on family history (e.g. BRCAPRO),
      ii. Known BRCA1 or BRCA2 gene mutation,
      iii. First-degree relative (parent, brother, sister, or child) with a BRCA1 or BRCA2 gene mutation, but have not had genetic testing themselves,
      iv. Radiation therapy to the chest when they were between the ages of 10 and 30 years, or
v. Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, or have first-degree relatives with one of these syndromes.

b. Breast MRI can also be reimbursed:
   i. When used to better assess areas of concern on a mammogram; or
   ii. For evaluation of a client with a past history of breast cancer after completing treatment.

c. Breast MRI should never be done alone as a breast cancer screening tool.

d. The BCCP will not reimburse for MRI of the breast for:
   i. Surveillance of breast findings (for example, the program will not reimburse for MRI follow-up every 3-6 months for a surgical consult of “benign findings”); or
   ii. Evaluation of silicone breast implant integrity.

3. The BCCP will reimburse for a surgical or breast specialist consultation for a woman who has a negative mammogram but who has persistent, unexplained, localized pain in the breast.

4. BCCP funds surgical consultations or follow-up visits intended to confirm or rule out breast cancer when screening tests yield abnormal results. BCCP will:
   a. Reimburse a maximum of two consults or visits to the same breast surgeon for the same breast problem (initial consultation plus a follow-up consultation).
   b. Reimburse follow-up of post-operative/post-biopsy complications of infection, hematoma, etc., following a BCCP-funded biopsy.
   c. Consider reimbursement on a case-by-case basis for follow-up surgical visits where the surgical pathology may be associated with recurrence or the presence of a more severe abnormality in the breast (e.g. certain types of atypia, phyllodes tumors) and the surgeon recommends short-term follow-up (every 3-6 months) for a maximum of 12 months.
   d. Not reimburse for on-going surveillance for those cases in which the medical case manager or surgeon recommends frequent follow-up visits for surveillance based on a benign breast condition that is considered chronic and or based on a woman’s risk factors.

5. The BCCP will reimburse for immunohistochemical (IHC) stains as indicated below:
   a. When cancer is diagnosed on the biopsy: the BCCP will reimburse for IHC stains ordered by the clinician or pathologist.
   b. When cancer is suspected or needs to be ruled out: IHC should not be used reflexively to evaluate every breast biopsy. IHC is best used when ordered by the pathologist where IHC will clarify an ambiguous pathologic diagnosis. The most frequent use of this is where the pathologist wants to know whether an adenoma or papilloma harbors invasive disease, or whether the tumor is ductal or lobular. The BCCP will reimburse in these cases but may request more information to justify the use of IHC.
This page intentionally left blank
Attachment A

Flow Charts
of the Maryland Breast and Cervical Cancer Program:

Management of Clinical Breast Examination and Mammogram Results

I. Management when Clinical Breast Examination is Normal/Benign Findings

II. Management when Clinical Breast Examination is Abnormal
Management of Clinical Breast Exam and Mammogram Results:

Clinical Breast Examination: Normal or Benign Findings

Women who:
- are asymptomatic; and
- have implant(s), fibrocystic changes, mastitis, "lumpy" breasts, family history of breast cancer (premenopausal breast cancer in sister/mother), prior benign biopsy (within past year) when surgeon or radiologist recommends screening mammogram.

Screening mammogram

Diagnostic mammogram

Mammogram Results

BI-RADS 0: Needs additional imaging evaluation
- Follow up per radiologist:
  - Diagnostic work-up (spot compression, magnification, special views, ultrasound, aspiration...)
  - Follow-up based on revised BI-RADS category

BI-RADS 1: Negative
- Annual follow-up: CBE with screening mammogram (if asymptomatic)
  - See BI-RADS 1, 2 or See BI-RADS 3 or See BI-RADS 4 or 5 above.

BI-RADS 2: Benign Finding
- Follow-up per radiologist:
  - CBE with imaging (if asymptomatic)
  - Further follow-up per surgeon

BI-RADS 3: Probably benign--short interval follow-up suggested
- Follow up per radiologist (usually 6 month repeat imaging)
  - Refer to surgeon or breast specialist

BI-RADS 4: Suspicious Abnormality – Biopsy Should Be Considered
BI-RADS 5: Highly Suggestive of Malignancy – Appropriate Action Should Be Taken
- Radiologist communicates findings to the patient, the referring physician
  - Image-guided biopsy
    - BI-RADS 5: AND Negative biopsy (that is, biopsy is not cancer, LCIS or atypical ductal hyperplasia)
    - BI-RADS 4: Positive biopsy (invasive cancer or DCIS)
      - Surgeon performs biopsy
      - Positive biopsy (invasive cancer or DCIS)
        - BI-RADS 4 or 5 with:
          - Negative biopsy
          - biopsy that is LCIS or atypical ductal hyperplasia
            - Further follow-up per surgeon

Management and Treatment of Cancer
Surgeon stages and initially manages breast cancer;
- Stage 0 must be offered oncologist consult
- Stage 1-4 must see oncologist

*Please refer to The Minimal Clinical Elements for Breast Cancer Detection and Diagnosis, Section II, C, number 4 page 7 for further details and program coverage.

Negative biopsy
  - BI-RADS 1, 2 or See BI-RADS 3 or See BI-RADS 4 or 5 above.

Positive biopsy
  - BI-RADS 4 or 5 with:
    - Negative biopsy
    - biopsy that is LCIS or atypical ductal hyperplasia
      - Further follow-up per surgeon

CBE, pathology and imaging results are discordant:
- Refer to surgeon or breast specialist.
  - CBE, pathology and imaging results are concordant:
    - Radiologist and primary care provider recommend next steps:
      - Offer referral to surgeon or breast specialist.

DCIS: Ductal carcinoma in situ
LCIS: Lobular carcinoma in situ
Management of Clinical Breast Exam and Mammogram Results:

Clinical Breast Examination: Abnormal (other than Normal or Benign Finding)**

Diagnostic mammogram (always); with Ultrasound, if recommended

CBE, Mammogram, and Ultrasound Results

** "Abnormal Clinical Breast Exam" includes:
- Nipple discharge that is bloody, crystal clear, or of any color if unilateral, single duct, and spontaneous;
- Discrete palpable mass—suspicious for cancer
- Nipple/areolar scaliness
- Skin dimpling/retraction

Management and Treatment of Cancer
Surgeon stages and initially manages breast cancer;
- Stage 0 must be offered oncologist consult
- Stage 1-4 must see oncologist

DCIS: Ductal carcinoma in situ
LCIS: Lobular carcinoma in situ

* Please refer to The Minimal Clinical Elements for Breast Cancer Detection and Diagnosis, Section II, C, number 4 page 7 for further details and program coverage.